Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

HLA B7 anticorps

HLA B7 Reactivité: Humain, Non-Human Primate FACS Hôte: Souris Monoclonal BB7-1 unconjugated
N° du produit ABIN1027673
  • Antigène Voir toutes HLA B7 Anticorps
    HLA B7 (HLA Class I B7 Alpha (HLA B7))
    Reactivité
    • 13
    • 3
    • 2
    • 2
    • 1
    Humain, Non-Human Primate
    Hôte
    • 11
    • 2
    Souris
    Clonalité
    • 11
    • 2
    Monoclonal
    Conjugué
    • 7
    • 4
    • 2
    Cet anticorp HLA B7 est non-conjugé
    Application
    • 9
    • 3
    • 2
    • 1
    • 1
    Flow Cytometry (FACS)
    Specificité
    The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
    Réactivité croisée (Details)
    Human, Non-Human Primates
    Purification
    Purified by protein-A affinity chromatography.
    Pureté
    > 95 % (by SDS-PAGE)
    Immunogène
    Papain solubilised HLA-A2, B7
    Clone
    BB7-1
    Isotype
    IgG1
    Top Product
    Discover our top product HLA B7 Anticorps primaire
  • Indications d'application
    Flow cytometry: Recommended dilution: 1-4 μg/mL.
    Restrictions
    For Research Use only
  • Concentration
    1 mg/mL
    Buffer
    Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Conseil sur la manipulation
    Do not freeze.
    Stock
    4 °C
    Stockage commentaire
    Store at 2-8°C. Do not freeze.
  • Cortez-Gonzalez, Sidney, Adotevi, Sette, Millard, Lemonnier, Langlade-Demoyen, Zanetti: "Immunogenic HLA-B7-restricted peptides of hTRT." dans: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).

    de la Salle, Saulquin, Mansour, Klayme, Fricker, Zimmer, Cazenave, Hanau, Bonneville, Houssaint, Lefranc, Naman: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." dans: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).

    Rini, Selk, Vogelzang: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." dans: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).

    Trapani, Vaughan, Tait, McKenzie: "Immunoradiometric assay for the rapid detection of HLA-B27." dans: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).

    Storkus, Alexander, Payne, Dawson, Cresswell: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).

  • Antigène
    HLA B7 (HLA Class I B7 Alpha (HLA B7))
    Autre désignation
    HLA-B7 (HLA B7 Produits)
    Synonymes
    anticorps AS, anticorps HLAB, anticorps SPDA1, anticorps major histocompatibility complex, class I, B, anticorps HLA-B
    Sujet
    HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.
    Pathways
    Human Leukocyte Antigen (HLA) in Adaptive Immune Response
Vous êtes ici:
Support technique